Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Steven Sun"'
Autor:
John Gerecitano, Jodi Carey, Christopher Major, Peter Johnson, Songbai Wang, Pier Luigi Zinzani, Wyndham H. Wilson, Steven Sun, Jessica Vermeulen, S. Martin Shreeve, Louis M. Staudt, Laurie H. Sehn, Michael Schaffer, Brendan P. Hodkinson, Sriram Balasubramanian
Publikováno v:
Br J Haematol
We assessed the concordance between immunohistochemistry (IHC) and gene expression profiling (GEP) for determining diffuse large B-cell lymphoma (DLBCL) cell of origin (COO) in the phase III PHOENIX trial of rituximab plus cyclophosphamide, doxorubic
Autor:
Hervé Avet-Loiseau, Steven Sun, Torben Plesner, Andrew Spencer, Aurore Perrot, Thierry Facon, Rachel Kobos, Philippe Moreau, Saad Z. Usmani, Meletios A. Dimopoulos, Shinsuke Iida, Jianping Wang, Maria Krevvata, Niels W.C.J. van de Donk, Vania Hungria, Maria-Victoria Mateos, Katja Weisel, Bruno Paiva, Nizar J. Bahlis, Michele Cavo, Christoph Heuck, Nikhil C. Munshi, Jesús F. San-Miguel, Shaji Kumar, M. Qi, Pieter Sonneveld, Jon Ukropec
Publikováno v:
Cavo, M, San-Miguel, J, Usmani, S Z, Weisel, K, Dimopoulos, M A, Avet-Loiseau, H, Paiva, B, Bahlis, N J, Plesner, T, Hungria, V, Moreau, P, Mateos, M-V, Perrot, A, Iida, S, Facon, T, Kumar, S, van de Donk, N W C J, Sonneveld, P, Spencer, A, Krevvata, M, Heuck, C, Wang, J, Ukropec, J, Kobos, R, Sun, S, Qi, M & Munshi, N 2022, ' Prognostic value of minimal residual disease negativity in myeloma : combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA ', Blood, vol. 139, no. 6, pp. 835-844 . https://doi.org/10.1182/blood.2021011101
Blood, 139(6), 835-844. American Society of Hematology
Cavo, M, San-Miguel, J F F, Usmani, S Z, Weisel, K C, Dimopoulos, M A A, Avet-Loiseau, H, Paiva, B, Bahlis, N J, Plesner, T, Hungria, V T D M, Moreau, P, Mateos, M V, Perrot, A, Iida, S, Facon, T, Kumar, S K, van de Donk, N W C J, Sonneveld, P, Spencer, A, Krevvata, M, Heuck, C, Wang, J, Ukropec, J, Kobos, R, Sun, S, Qi, M & Munshi, N C 2022, ' Prognostic value of minimal residual disease negativity in myeloma : combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA ', Blood, vol. 139, no. 6, pp. 835-844 . https://doi.org/10.1182/blood.2021011101
Blood, 139(6), 835-844. American Society of Hematology
Cavo, M, San-Miguel, J F F, Usmani, S Z, Weisel, K C, Dimopoulos, M A A, Avet-Loiseau, H, Paiva, B, Bahlis, N J, Plesner, T, Hungria, V T D M, Moreau, P, Mateos, M V, Perrot, A, Iida, S, Facon, T, Kumar, S K, van de Donk, N W C J, Sonneveld, P, Spencer, A, Krevvata, M, Heuck, C, Wang, J, Ukropec, J, Kobos, R, Sun, S, Qi, M & Munshi, N C 2022, ' Prognostic value of minimal residual disease negativity in myeloma : combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA ', Blood, vol. 139, no. 6, pp. 835-844 . https://doi.org/10.1182/blood.2021011101
We explored minimal residual disease (MRD) in relapsed/refractory multiple myeloma (RRMM) and transplant-ineligible (TIE) newly diagnosed multiple myeloma (NDMM) using data from 4 phase 3 studies (POLLUX, CASTOR, ALCYONE, and MAIA). Each study previo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45c64997dd452605ab785f5859d6df78
https://research.vumc.nl/en/publications/4fe089e5-72a4-42e8-a3c4-bb08bb52d9fe
https://research.vumc.nl/en/publications/4fe089e5-72a4-42e8-a3c4-bb08bb52d9fe
Autor:
Olga Samoilova, Marie Sarah Dilhuydy, Andre Goy, Monelle Tamegnon, Asher Chanan-Khan, Michael Hallek, Mariya Salman, Simon Rule, Kerri Nottage, Anthony R. Mato, Graeme Fraser, Natasha Schuier, Javier Loscertales, Steven Sun, Angela Howes, Sebastian Grosicki, Ann Janssens, Miguel A. Pavlovsky, Sriram Balasubramanian, Fatih Demirkan, Abraham Avigdor, Rodrigo Santucci Silva, Nancy L. Bartlett, Jiri Mayer, Anne Connor, Paula Cramer
Publikováno v:
Leukemia & Lymphoma. 61:3188-3197
We report final analysis outcomes from the phase 3 HELIOS study (NCT01611090). Patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma without deletion 17p (n = 578) were randomized 1:1 to 420 mg daily ibrutinib or p
Autor:
Himal Amin, Nizar J. Bahlis, Shinsuke Iida, Priya Ramaswami, Jesús F. San-Miguel, Torben Plesner, Andrew Spencer, Jon Ukropec, Sagar Lonial, Xiang Qin, Saad Z. Usmani, Ming Qi, Christopher Chiu, Tineke Casneuf, Katja Weisel, M. Qi, Maria Krevvata, Rachel Kobos, Philippe Moreau, Hervé Avet-Loiseau, Steven Sun, Sonali Trivedi
Publikováno v:
Avet-Loiseau, H, San-Miguel, J, Casneuf, T, Iida, S, Lonial, S, Usmani, S Z, Spencer, A, Moreau, P, Plesner, T, Weisel, K, Ukropec, J, Chiu, C, Trivedi, S, Amin, H, Krevvata, M, Ramaswami, P, Qin, X, Qi, M, Sun, S, Qi, M, Kobos, R & Bahlis, N J 2021, ' Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma : Analysis of POLLUX and CASTOR ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 39, no. 10, pp. 1139-1149 . https://doi.org/10.1200/JCO.20.01814
PURPOSE In relapsed and/or refractory multiple myeloma, daratumumab reduced the risk of progression or death by > 60% in POLLUX (daratumumab/lenalidomide/dexamethasone [D-Rd]) and CASTOR (daratumumab/bortezomib/dexamethasone [D-Vd]). Minimal residual
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1f9158e42f9af71740e2dd3135ee07c
https://findresearcher.sdu.dk:8443/ws/files/181658741/Open_Access_Version.pdf
https://findresearcher.sdu.dk:8443/ws/files/181658741/Open_Access_Version.pdf
Autor:
Sirpa Leppä, Su-Peng Yeh, Ronit Gurion, Mehmet Turgut, Sriram Balasubramanian, Laurie H. Sehn, Anas Younes, Sen Hong Zhuang, Xiaonan Hong, Pier Luigi Zinzani, Andres Lopez-Hernandez, Shinya Rai, Caterina Patti, S. Martin Shreeve, Wojciech Jurczak, David Belada, Matthew C. Cheung, Olga Samoilova, Cheolwon Suh, Jessica Vermeulen, Louis M. Staudt, Jodi Carey, Catherine Thieblemont, Peter Johnson, C.S. Chiattone, Ulrich Dührsen, Grace Liu, Wyndham H. Wilson, Steven Sun, Jun Zhu
Publikováno v:
Journal of Clinical Oncology. 37:1285-1295
60th Annual Meeting of the American-Society-of-Hematology (ASH) -- DEC 01-04, 2018 -- San Diego, CA Jurczak, Wojciech/0000-0003-1879-8084; Johnson, Peter/0000-0003-2306-4974; ZINZANI, PIER LUIGI/0000-0002-2112-2651; Leppa, Sirpa/0000-0002-8265-511X W
Autor:
Nikki A. Deangelis, Shaji Kumar, M. Qi, Thierry Facon, Hervé Avet-Loiseau, Steven Sun, Jesús F. San-Miguel, Rachel Kobos, Hang Quach, Maria Krevvata, Christoph Heuck, Saad Z. Usmani, Rian Van Rampelbergh, Michele Cavo, Anupa Kudva, Bruno Paiva, Huiling Pei, Andrzej Jakubowiak, Ming Qi, Maria-Victoria Mateos, Jon Ukropec, Cyrille Touzeau, Jianping Wang, Priya Ramaswami, Gordon Cook, Meletios A. Dimopoulos, Nizar J. Bahlis
Publikováno v:
Blood. 139(4)
In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA (daratumumab/lenalidomide/dexamethasone [D-Rd]) and 58% in ALCYONE (daratumumab/bortezomib/mel
Autor:
Xiaoyan Ke, Angela Howes, Mariya Salman, Lugui Qiu, Jianyong Li, Jie Jin, Xiao-Jun Huang, Daobin Zhou, Hanyun Ren, Ming Hou, Yu Hu, Yingmin Liang, Peng Wu, Junmin Li, Chunting Zhao, Yue Lv, Jingzhao Wang, Steven Sun, Jianda Hu, Jianmin Wang, Aining Sun, Ting Liu, Xiequn Chen
Publikováno v:
Cancer Medicine
In the Asia‐Pacific region, treatment options are limited for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Rituximab is widely used in this setting when purine analog‐based therapies are n
Autor:
Fong Clow, Danelle F. James, Elizabeth Faust, Sen Hong Zhuang, Steven Sun, Margaret Doyle, Mann Fung, Samiyeh Price, Urte Gayko, Samina Bari
Publikováno v:
Annals of the New York Academy of Sciences. 1358
Ibrutinib is a first-in-class oral covalent inhibitor of Bruton's tyrosine kinase that has demonstrated clinical benefit for many patients with B cell malignancies. Positive results in initial trials led the U.S. Food and Drug Administration to grant
Publikováno v:
Clinical Journal of the American Society of Nephrology. 5:598-606
Background and objectives: Extended-interval dosing of epoetin alfa (EPO) is commonly used to treat anemia in patients with chronic kidney disease (CKD). This study aimed to demonstrate that EPO dosed every 2 weeks (Q2W) and every 4 weeks (Q4W) was n
Autor:
Anas Younes, Sen Hong Zhuang, Kevin Bellew, Wyndham H. Wilson, Steven Sun, Laurie H. Sehn, Tahamtan Ahmadi, Randy D. Gascoyne, Peter Johnson, Jessica Vermeulen, Louis M. Staudt, Pier Luigi Zinzani
Publikováno v:
Journal of Clinical Oncology. 32:TPS8615-TPS8615
TPS8615^ Background: The standard regimen for frontline treatment of DLBCL is R-CHOP, which results in a complete response (CR) in 76% of patients and a 10-year overall survival (OS) rate of 44%. D...